Loading...
Protagenic Therapeutics, Inc.
PTIXW•NASDAQ
Healthcare
Biotechnology
$0.06
$0.010(19.60%)
Protagenic Therapeutics, Inc. (PTIXW) Company Profile & Overview
Explore Protagenic Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Protagenic Therapeutics, Inc. (PTIXW) Company Profile & Overview
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
SectorHealthcare
IndustryBiotechnology
CEODr. Garo H. Armen Ph.D.
Contact Information
Company Facts
1 Employees
IPO DateApr 27, 2021
CountryUS
Actively Trading